Myriad Genetics signaled a broadened rollout of its precise MRD strategy in breast cancer following AACR readouts. The company is exploring wider adoption of its ultrasensitive ctDNA testing to assess relapse risk and guide treatment escalation or de-escalation. The MRD narrative continues to shift the endpoint set for oncology development, as assays that can detect low-level residual disease may influence trial designs as well as how clinicians respond in routine practice. Myriad’s position depends on performance characteristics across lines of therapy and treatment classes. As MRD platforms race toward clinical adoption, Myriad’s next step is to convert conference signals into broader evidence packages and payer-relevant workflows.